AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drugmaker believes it can almost double revenue by 2030.
The pharmaceutical giant also plans to release 20 new drugs by 2030, half of which will treat cancer, Soriot said.
The company recently released promising results about several of its cancer drugs at the American Society of Clinical Oncology's annual meeting, including ones for lung and breast cancers.
Soriot said researchers are quickly developing new and promising cancer treatments.
He said new cell therapies have the potential to cure patients, and he also pointed to antibody-drug conjugates — which, unlike chemotherapy, aim to target cancer cells while sparing healthy ones.
Persons:
Pascal Soriot, CNBC's Jim Cramer, we're, Soriot
Organizations:
AstraZeneca, American Society, Clinical, CNBC